Main Article Content
Background: The high costs of oncology care can lead to financial stress and have deleterious effects on the well-being of patients and their families. However, only a handful of financial assistance programs for cancer patients have been implemented and evaluated to date.
Recent findings: Key features of reported programs include instrumental support through financial navigation or education for patients, and financial or charitable support for healthcare costs. Only one of the programs successfully reduced actual out-of-pocket costs for patients, though others were associated with psychosocial benefits or increased knowledge of financial resources. Four of the 5 programs evaluated to date were pilot studies with small sample sizes, and most lack control groups for comparison.
Conclusions: Additional studies are needed that include larger sample sizes and with comparison groups of cancer patients in order to determine whether the counseling and navigator programs are effective in addressing financial distress in this patient population. Of particular interest are programs designed for low-income patients and those who lack health care insurance. Financial assistance programs that implement solutions at different levels of the healthcare system (individual patients, providers, healthcare institutions) are more likely to be effective. Multi-level interventions are needed that address the systems in which patients access care, the actual costs of services and drugs, and the individual needs of patients in order to reduce financial hardship for cancer patients.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
- Zafar SY. Financial toxicity of cancer care: it’s time to intervene. Journal of the National Cancer Institute, 2016, 108(5): 1-4. https://doi.org/10.1093/jnci/djv370
- Dean LT, Schmitz KH, Frick KD, et al. Consumer credit as a novel marker for economic burden and health after cancer in a diverse population of breast cancer survivors in the USA. Journal of Cancer Survivorship, 2018, 12: 306-315. https://doi.org/10.1007/s11764-017-0669-1
- Coughlin SS and Dean LT. Cancer survivorship care plans, financial toxicity, and financial planning alleviating financial distress among cancer survivors. Supportive Care in Cancer, 2019, 27: 1969-1971. https://doi.org/10.1007/s00520-019-04703-6
- Coughlin SS, Moore JX and Cortes JE. Addressing financial toxicity in oncology care. Journal of Hospital Management and Health Policy 2020, in press. https://doi.org/10.21037/jhmhp-20-68
- Desai A and Gyawali B. Financial toxicity of cancer treatment: moving the discussion from acknowledge of the problem to identifying solutions. EClinicalMedicine 2020, in press. https://doi.org/10.1016/j.eclinm.2020.100269
- Shankaran V, Leahy T, Steelquist J, et al. Pilot feasibility study of an oncology financial navigation program. Journal of Oncology Practice, 2018, 14(2): 122-129. https://doi.org/10.1200/JOP.2017.024927
- Pisu M, Azuero A, McNees P, et al. The out of pocket cost of breast cancer survivors: a review. Journal of Cancer Survivorship, 2010, 4: 202-209. https://doi.org/10.1007/s11764-010-0125-y
- Carrera PM, Kantarjian HM and Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA: A Cancer Journal for Clinicians, 2018, 68(2): 153-165. https://doi.org/10.3322/caac.21443
- Jagsi R, Pottow JA, Griffith KA, et al. Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. Journal of Clinical Oncology, 2014, 32(12): 1269-1276. https://doi.org/10.1200/JCO.2013.53.0956
- Altice CK, Banegas MP, Tucker-Seley RD, et al. Financial hardships experienced by cancer survivors: a systematic review. Journal of the National Cancer Institute, 2017, 109(2). https://doi.org/10.1093/jnci/djw205
- Watabayashi K, Steelquist J and Overstreet KA. A pilot study of a comprehensive financial navigation program in patients with cancer and caregivers. National Comprehensive Cancer Network, 2020, 18(19): 1366-1373. https://doi.org/10.6004/jnccn.2020.7581
- de Souza JA, Yap BJ, Wroblewski K, et al. Measuring financial toxicity as a clinically relevant patientreported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). Cancer, 2017, 123(3): 476-484. https://doi.org/10.1002/cncr.30369
- ThorntonMand Travis SS. Analysis of the reliability of the modified caregiver strain index. The Journals of Gerontology: Series B, 2003, 58(2): 127-132. https://doi.org/10.1093/geronb/58.2.S127
- Sadigh G, Gallagher K, Obenchain J, et al. Pilot feasibility study of an oncology financial navigation program in brain cancer patients. Journal of the American College of Radiology, 2019, 16(10): 1420- 1424. https://doi.org/10.1016/j.jacr.2019.07.014
- Yezefski T, Steelquist J, Watabayashi K, et al. Impact of trained oncology financial navigators on patient out-of-pocket spending. The American Journal of Managed Care, 2018, 24(5 Suppl): 74-79.
- Kircher SM, Yarber J, Rutsohn J, et al. Piloting a financial counseling intervention for patients with cancer receiving chemotherapy. Journal of Oncology Practice, 2019, 15(3): e202-e210. https://doi.org/10.1200/JOP.18.00270
- Lentz R, Benson AB and Kircher S. Financial toxicity in cancer care: prevalence, causes, consequences, and reduction strategies. Journal of Surgical Oncology, 2018, 120(1): 85-92. https://doi.org/10.1002/jso.25374
- Gao L, Joseph J, Santoro-Levy M, et al. Use of a prescription-assistance program for medically uninsured patients with cancer: case study of a public hospital experience in New York State. Journal of Oncology Practice, 2014, 10(2): 104. https://doi.org/10.1200/JOP.2013.001101
- Zafar SY and Peppercorn JM. Patient financial assistance programs: a path to affordability or a barrier to accessible cancer care? Journal of Clinical Oncology, 2017, 35(19): 2113-2116. https://doi.org/10.1200/JCO.2016.71.7280
- Dean LT, George M, Lee KT, et al. Why individual-level interventions are not enough: systems-level determinants of oral anticancer medication adherence. Cancer, 2020, 126(16): 3606-3612. https://doi.org/10.1002/cncr.32946